Loading…
← CockpitCompetitor Analysis › SLS SELLAS Life Sciences Group, Inc.Open in the cockpit ↗

SELLAS Life Sciences Group, Inc.SLSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing cancer immunotherapies targeting the WT1 tumor antigen for blood and solid cancers.

Momentum leader 98
Mkt cap
$3.66B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$211M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 18.8%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$17.95
1D-6.3%
1W+113.2%
1M+49.8%
3M+34.0%
6M+100.1%
YTD+376.1%
1Y+1,173.0%
ATR %12.8%
Beta1.37
52w lowhigh27.9% off high

What SELLAS Life Sciences does

Clinical-stage biotech developing cancer immunotherapies targeting the WT1 tumor antigen for blood and solid cancers.

Has no product sales: it is funded by money raised from investors, so cash runway and each round of financing matter. Galinpepimut-S is its lead drug in a late-stage trial in acute myeloid leukaemia, where results decide whether it can seek approval or a partner.

Products and services

  • Galinpepimut-S (AML/mesothelioma)
  • Other WT1-targeted pipeline

Where it sits in the supply chain

  • Biopharma R&D
  • Cancer immunotherapy (WT1-targeted…
  • Clinical development

What could go right

  • Positive pivotal trial data
  • Partnership/licensing deal

What could go wrong

  • Binary clinical trial risk
  • Cash runway/dilution risk

Moat: none (IP / patents). Pre-revenue biotech; success depends entirely on unproven late-stage trial outcomes.

Headquarters: New York, New York, US · Founded: 2017 · Employees: 13

Named competitors

SELLAS Life Sciences at a glance

Size SELLAS Life Sciences (SLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.66B, the 1395th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.95 on 18 Nov 2026.

Performance Over six months the shares gained 100.1%, against +1.6% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 19 in its peer set.

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020025021 May 202621 Aug 202618 Nov 2026SLS 237Peer median 103
Six months, rebased to 100: SELLAS Life Sciences against the median of its 20 peers (local-currency closes).

SELLAS Life Sciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$1.00M
Revenue growth———-100%—
Gross profit$0$0$0$0$443,000
EBITDA-$39.4M-$28.3M-$31.5M-$37.9M-$31.5M
Net income-$35.8M-$26.9M-$30.9M-$37.3M-$41.3M
Free cash flow-$27.3M-$28.4M-$35.4M-$36.9M-$28.3M
Capital expenditure$0$0$0$5.50M$4.50M
Total debt$599,000$1.00M$1.00M$906,000$945,000

Quarterly statements and history in the cockpit →

SELLAS Life Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%OGNXENE60052133201513TARSROVI600329WOCKPHARMA688336ACUTAAS1877ARQTAMLXVRDNSLS6-month return →1-month return →
Up and to the right = strong over both horizons. SELLAS Life Sciences is the large dot.

SELLAS Life Sciences competitors and peer comparison

Head to head with its named competitors (SLS vs BMY vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
SELLAS Life Sciences SLS$3.66B+100%n/an/an/an/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Merck & MRK$340B+23%+5%18%5.7×8.3%

How SELLAS Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SELLAS Life Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureSLSPeer medianRank in peer set
1-month return+49.8%-0.2%highest of 21
6-month return+100.1%+1.6%highest of 19
Distance from 52-week high-27.9%-23.4%8th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%2.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%5.2×34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%4.2×1.2%+12.1%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%5.1×16.2%-5.8%
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%5.5×0.9%+45.1%
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%8.4×n/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%106.6×n/an/a
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%27.6×57.4%+3.1%
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%2.6×-3.4%+10.6%

Questions

Who are SELLAS Life Sciences's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Merck (MRK). The cockpit's measured peer set (industry) also includes Organon & (OGN), Xenon Pharmaceuticals (XENE), Zhejiang Huahai Pharmaceutical (600521.SS), China Resources Pharmaceutical (3320.HK), Livzon Pharmaceutical (1513.HK), Tarsus Pharmaceuticals (TARS).
How has SELLAS Life Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned +100.1% against +1.6% for the median peer; over one year +1,173.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.